AstraZeneca to share new drug data at ACC 2018

AstraZeneca has announced that it will be sharing new drug development insights at this year's American College of Cardiology (ACC) Scientific Session and Expo.

During the conference in Orlando, which runs from March 10th to 12th, the company will present phase III data and landmark real-world evidence from Asia, the Middle-East and North America analysing clinical approaches to tackling cardiovascular diseases.

A total of ten abstracts have been accepted, including data from the CVD-REAL 2 study, which has evaluated the risk of hospitalisation for heart failure and death from any cause in patients with type 2 diabetes treated with SGLT-2 inhibitors.

Results from the phase III TREAT trial will also be shared, exploring the safety of Brilinta in patients treated with pharmacological thrombolysis. Findings from the ARTEMIS trial, meanwhile, will address the impact of patient copayment reduction on P2Y12 inhibitor persistence and clinical outcomes after a heart attack.

Ludovic Helfgott, vice-president of cardiovascular, renal and metabolic diseases at AstraZeneca, said: "Once again, we're bringing to the ACC community a breadth of distinctive science that refines our understanding of cardiovascular and metabolic diseases in order to advance clinical practice."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.